TABLE 2.
Group or test | % concordance with MIF result | % specificity | % sensitivity | PPV (%) | NPV (%) |
---|---|---|---|---|---|
Collective 2 | |||||
IgG | |||||
SeroCP Quant | 94 | 87 | 95 | 97 | 81 |
SeroCP | 91 | 67 | 97 | 93 | 83 |
sELISA | 90 | 87 | 91 | 97 | 68 |
rELISA | 65 | 73 | 63 | 91 | 31 |
IgA | |||||
SeroCP Quant | 86 | 85 | 89 | 96 | 65 |
SeroCP | 95 | 95 | 95 | 98 | 86 |
Collective 3 | |||||
SeroCP Quant | 96 | 67 | 100 | 96 | 100 |
SeroCP | 96 | 67 | 100 | 96 | 100 |
Eighty samples from collective 2 and 50 samples from collective 3 were analyzed for C. pneumoniae antibodies by the indicated ELISA, and assay performance was evaluated on the basis of the gold standard MIF test.